1 |
Aktekin, T., Dutta, D.K. and Sohl, J.E. (2017) Entrepreneurial firms and financial attractiveness for securing debt capital: a Bayesian analysis, Venture Capital, 20(1), 1-24.
|
2 |
Amram, M. and Kulatilaka, N. (2000) Strategy and shareholder value creation: the real options frontier, Journal of Applied Corporate Finance, 13(2), 15-28.
DOI
|
3 |
Audretsch, B. (1998) Agglomeration and the location of innovative activity, Oxford Review of Economic Policy, 14(2), 18-29.
DOI
|
4 |
Audretsch, D.B., Aldridge, T.T. and Sanders, M. (2011) Social capital building and new business formation: a case study in silicon valley, International Small Business Journal, 29(2), 152-169.
DOI
|
5 |
Auerswald, P.E. and Branscomb, L.M. (2003) Valleys of death and darwinian seas: financing the invention to innovation transition in the united states, Journal of Technology Transfer, 28(3-4), 227-239.
DOI
|
6 |
Binder, G. and Bashe, P. (2008) Science Lessons: What the Business of Biotech Taught Me about Management, Cambridge, MA: Harvard Business School Press.
|
7 |
Black, F. and Scholes, M. (1973) The pricing of options and corporate liabilities, Journal of Political Economy, 81(3), 637-659.
DOI
|
8 |
Block, F. (2008) Swimming against the current: the rise of a hidden developmental state in the united states, Politics and Society, 36(2), 169-206.
DOI
|
9 |
Bogdan, B. and Villiger, R. (2010) Valuation in Life Sciences: A Oractical Guide, Berlin: Springer.
|
10 |
Bowman, E.H. and Moskowitz, G.T. (2001) Real options analysis and strategic decision making, Organization Science, 12(6), 772-777.
DOI
|
11 |
Brindley, D. and Davie, N. (2009) Regenerative medicine through a crisis: social perception and the financial reality, Rejuvenation Research, 12(6), 455-461.
DOI
|
12 |
Castellaneta, F. and Gottschalg, O. (2014) Does ownership matter in private equity? the sources of variance in buyouts' performance, Strategic Management Journal, 37(2), 330-348.
DOI
|
13 |
Copeland, T.E. and Antikarov, V. (2001) Real Options, New York: Texere.
|
14 |
Dixit, A. and Pindyck, R.S. (1994) Investment Under Uncertainty, Princeton, NJ: Princeton University Press.
|
15 |
Etzkowitz, H. (2006) The new visible hand: an assisted linear model of science and innovation policy, Science and Public Policy, 33(5), 310-320.
DOI
|
16 |
Feldman, M.P. (2003) The locational dynamics of the US biotech industry: knowledge externalities and the anchor hypothesis, Industry and Innovation, 10(3), 311-328.
DOI
|
17 |
Finkbeiner, S. (2010) Bridging the valley of death of therapeutics for neurode-generation, Nature Medicine, 16, 1227-1232.
DOI
|
18 |
Garnsey, E.W., Galloway, S.C. and Mathisen, S.H. (2006) Flexibility and specialization in question; birth, growth and death rates of Cambridge new technology-based firms 1988-92, Entrepreneurship and Regional Development, 6(1), 81-107.
DOI
|
19 |
Hughes, S.S. (2011) Genentech: The Beginnings of Biotech (Synthesis), Chicago: University of Chicago Press.
|
20 |
Jagle, A.J. (1999) Shareholder value, real options, and innovation in technology-intensive companies, R&D Management, 29(3), 271-288.
DOI
|
21 |
Kester, W.C. (1984) Today's options for tomorrow's growth, Harvard Business Review, 62(2) March-April, 153-160.
|
22 |
Kruschke, J. (2014) Doing Bayesian Data Analysis: A Tutorial with R, JAGS, and Stan, 2nd ed., London: Academic Press.
|
23 |
Myers, S.C. (1977) Determinants of corporate borrowing, Journal of Financial Economics, 5(2), 147-176.
DOI
|
24 |
McGrath, R.G. (1999) Falling forward: real options reasoning and entrepreneurial failure, Academy of Management Review, 24(1), 13-30.
DOI
|
25 |
Merton, R.C. (2007) Theory of rational option pricing, Bell Journal of Economics, 4(1), 141-183.
|
26 |
Moran, N. (2007) Public sector seeks to bridge 'valley of death', Nature Biotechnology, 25(3), 266.
DOI
|
27 |
Ottoo, R.E. (1998) Valuation of internal growth opportunities: the case of a biotechnology company, Quarterly Review of Economics and Finance, 38(3), 615-633.
DOI
|
28 |
Perlitz, M., Peske, T. and Schrank, R. (1999) Real options valuation: the new frontier in R&D project evaluation? R&D Management, 29(3), 255-270.
DOI
|
29 |
Pisano, G.P. (2006) Science Business: The Promise, the Reality and the Future of Biotech, Cambridge, MA: Harvard Business School Press.
|
30 |
Teconomy Partners LLC, (2018) Strengthening Biopharmaceutical Innovation, PhRMA.
|
31 |
USA Securities and Exchange Commission (2017) EDGAR, Retrieved from https://www.sec.gov/edgar.shtml.
|
32 |
Vassolo, R.S., Anand, J. and Folta, T.B. (2004) Non-additivity in portfolios of exploration activities: a real options-based analysis of equity alliances in biotechnology, Strategic Management Journal, 25(11), 1045-1061.
DOI
|
33 |
Zhong, H., Liu, C., Zhong, J. and Xiong, H. (2018) Which startup to invest in: a personalized portfolio strategy, Annals of Operations Research, 263(1-2), 339-360.
DOI
|
34 |
Waluszewski, A. (2004) A competing or co-operating cluster or seven decades of combinatory resources? what's behind a prospering biotech valley?, Scandinavian Journal of Mangement, 20(1-2), 125-150.
DOI
|
35 |
Werth, B. (2014) The Antidote: Inside the World of New Pharma, New York: Simon & Schuster.
|